Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status

Cancer

Volumn 116, Issue 11, 2010, Pages 2645-2654

  Shoushtari, Asal ^a   Meeneghan, Mathew ^a   Sheng, Ke ^a   Moskaluk, Christopher A ^a   Thomas, Christopher Y ^a   Reibel, James F ^a   Levine, Paul A ^a   Jameson, Mark J ^a   Keeneand, Kimberly ^b   Read, Paul W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Human papillomavirus; Intensity modulated radiotherapy; Neck dissection; Oropharyngeal cancer; P16

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PROTEIN P16;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NECK DISSECTION; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; GENES, P16; HUMANS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM PROTEINS; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 77952836952     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25040     Document Type: Article

References (46)

1. The American Cancer Society Website. Available at: http://www.cancer.org/ downloads/STT/2008CAFFfinalsecured.pdf (page 4). Accessed February 11, 2009.
2. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for Human Papillomavirus-related and unrelated oral SCC in the United States. J Clin Oncol. 2008;26:612-619.
3. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143-1154.
4. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-754.
5. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and HPV infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004;108:766-772.
6. Fakhry C, Gillison ML. Clinical implications of HPV in head and neck cancers. J Clin Oncol. 2008;26:2606-2611.
7. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of HPV-associated cancers? Cancer. 2007;110: 1429-1435.
8. Ringstrom E, Peters E, Hasegawa M, et al. Human Papilloma type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8:3187-3192. (Pubitemid 35155029)
9. Gillison ML, Koch WM, Capone PR, et al. Evidence for a causal association between HPV and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:675-677.
10. Lee WT, Tubbs RR, Teker AM, et al. Use of in situ hybridization to detect HPV in HNSCC patients without a history of alcohol or tobacco. Arch Pathol Lab Med. 2008; 132:1653-1656.
11. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007; 120:1731-1738. (Pubitemid 46399359)
12. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of HPV in paraffin embedded head and neck cancer specimens. Int J Cancer. 2007;121:2465-2472.
13. Ragin CR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to HPV infection: review and meta-analysis. Int J Cancer. 2007;121:1813-1820. (Pubitemid 47417302)
14. Martinez I, Wang J, Hobson KF, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative OSCC. Eur J Cancer. 2007;43:415-432.
15. Denekamp J. Cell kinetics and radiation biology. Int J Radiat Biol Stud Phys Chem Med. 1986;49:357-380.
16. NCCN Clinical Practice Guidelines. Head and Neck Cancer Guidelines. Available at: http://www.nccn.org/professionals/physician-gls/PDF/head-and-neck. pdf. Accessed February 25, 2009.
17. Shoushtari A, Rahimi N, Schlesinger DJ, et al. Survey on HPV/P16 screening use in OSCC in the United States. Cancer. 2009 [Epub ahead of print].
18. Chao KS, Markman J, Haynie J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or 3-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907-916. (Pubitemid 32184597)
19. Chao KS, Huang CJ, Simpson JR, et al. IMRT reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001;61:275-280.
20. Eisbruch A, Terrell JE, Marsh LH, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695-704. (Pubitemid 32515326)
21. Henson BS, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol. 2001;37:84-93.
22. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head and neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2003;57:61-70. (Pubitemid 36959739)
23. Mell LK, Roeske JC, Mundt AJ. A survey of IMRT use in the United States. Cancer. 2003;98:204-211.
24. Mell LK, Mehrotra AK, Mundt AJ. Intensity modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104: 1296-1303.
25. De Arruda FF, Puri DR, Zhung J, et al. IMRT for the treatment of oropharyngeal carcinoma: the Memorial Sloan- Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2006;64:363-373.
26. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer. 2008;113:497-507.
27. Chao KS, Ozyigit G, Blanco AI, et al. IMRT for Oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004;59:43-50.
28. Garden A, Asper J, Morrison WH, et al. Disease control rates following IMRT for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438-444.
29. Yao M, Nguyen T, Buatti JM, et al. Changing failure patterns in OSCC treated with intensity modulated radiotherapy and implications for future research. Am J Clin Oncol. 2006;29:606-612.
30. Sanguineti G, Gunn GB, Endres EJ, et al. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008;72:737-746.
31. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with IMRT? An inter-era comparison. Int J Radiat Oncol Biol Phys. 2007;69:1032-1041.
32. Thomas CY, Read P, Petroni G, et al. Phase I study of capecitabine, carboplatin and IMRT for head and neck cancer. Anticancer Res. 2009;29:2869-2873.
33. Eisbruch A, Ship JA, D'Hondt E, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996;36:469-480. (Pubitemid 26359474)
34. Som PM, Curtin HD, Mancuso AA. An imaging-based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications. Arch Otolarngol Head Neck Surg. 1999;125:388-396.
35. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid sparing conformal and segmental IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46:1117-1126. (Pubitemid 30139420)
36. Sheng K, Chow MJ, Hunter G, et al. Is daily CT image guidance necessary for nasal cavity and nasopharyngeal radiotherapy: an investigation based on helical tomotherapy MVCT data. J Applied Clin Med Phys. 2008;9:2686-2690.
37. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45:577-587. (Pubitemid 29462636)
38. Sheng K, Molloy JA, Read PW. IMRT dosimetry of the head and neck: a comparison of treatment plans using linac-based IMRT and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2006;65:917-923.
39. Moskaluk CA, Stoler MH. Agarose mold embedding of cultured cells for tissue microarrays. Diag Mol Pathol. 2002; 11:234-238.
40. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV 16- and HPV 18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291.
41. Guimaraes MC, Goncalves MA, Soares CP, et al. Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions. J Histochem Cytochem. 2005;53:509-516.
42. Klussman JP, Gultekin E, Weissenborn SJ, et al. Expression of P16 protein identifies a distinct entity of tonsillar carcinomas associated with HPV. Am J Pathol. 2003;62:747-753. (Pubitemid 36237483)
43. Kumar B, Cordell K, Lee J, et al. EGFR, p16, HPV Titet, BclxL, and p53, sex, and smoking as indicators of therapy and survival in oropharyngeal cancer. J ClinOncol. 2008;6:3128-3137.
44. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18f- FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532-540. (Pubitemid 351520600)
45. Pigonon JP, le Maitre A, Maillard E, Bourhis J; MACHNC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92:4-14.
46. Shasha D, Harrison LB. Elective irradiation of the N0 neck in squamous cell carcinoma of the upper aerodigestive tract. Otolaryngol Clin North Am. 1998;31:803-813. (Pubitemid 28489089)